Literature DB >> 10225421

Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation.

C H Kim1, J H Kim, C Y Hsu, Y S Ahn.   

Abstract

Pyrrolidine dithiocarbamate (PDTC) is a potent inhibitor of nuclear factor kappa B (NF-kappaB) activation. PDTC inhibited basal NF-kappaB activity of endothelial cells. PDTC, however, failed to inhibit basal NF-kappaB activity after withdrawal of serum in the media, and the inhibitory effect of PDTC could be restored by addition of zinc. When various preparations of metal ion-EDTA were tested with PDTC in serum-containing media, only Zn-EDTA failed to block the inhibitory effect of PDTC. The dependence on zinc was also noted in PDTC inhibition of NF-kappaB stimulated by TNF alpha. These facts suggest that zinc is required for PDTC inhibition of NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225421     DOI: 10.1016/s0014-5793(99)00390-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-kappa B targeting in the alveolar epithelium.

Authors:  J J Haddad; B Safieh-Garabedian; N E Saadé; S C Land
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Pyrrolidine dithiocarbamate inhibits superoxide anion-induced pain and inflammation in the paw skin and spinal cord by targeting NF-κB and oxidative stress.

Authors:  Felipe A Pinho-Ribeiro; Victor Fattori; Ana C Zarpelon; Sergio M Borghi; Larissa Staurengo-Ferrari; Thacyana T Carvalho; Jose C Alves-Filho; Fernando Q Cunha; Thiago M Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflammopharmacology       Date:  2016-05-09       Impact factor: 4.473

3.  Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions.

Authors:  B M Krenn; B Holzer; E Gaudernak; A Triendl; F J van Kuppeveld; J Seipelt
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 4.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

5.  Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway.

Authors:  Xiaoning Si; Bruce M McManus; Jingchun Zhang; Ji Yuan; Caroline Cheung; Mitra Esfandiarei; Agripina Suarez; Andrew Morgan; Honglin Luo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate.

Authors:  Nadine Wiesener; Christin Zimmer; Nadine Jarasch-Althof; Peter Wutzler; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2010-12-21       Impact factor: 3.402

7.  Pyrrolidine dithiocarbamate inhibits herpes simplex virus 1 and 2 replication, and its activity may be mediated through dysregulation of the ubiquitin-proteasome system.

Authors:  Min Qiu; Yu Chen; Lin Cheng; Ying Chu; Hong-Yong Song; Zhi-Wei Wu
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

8.  Evidence that reactive oxygen species do not mediate NF-kappaB activation.

Authors:  Makio Hayakawa; Hiroshi Miyashita; Isao Sakamoto; Masatoshi Kitagawa; Hirofumi Tanaka; Hideyo Yasuda; Michael Karin; Kiyomi Kikugawa
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

9.  Zinc Inhibits Amyloid beta Production from Alzheimer's Amyloid Precursor Protein in SH-SY5Y Cells.

Authors:  Jinu Lee; Chul Hoon Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2009-06-30       Impact factor: 2.016

10.  Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections.

Authors:  B M Krenn; E Gaudernak; B Holzer; K Lanke; F J M Van Kuppeveld; J Seipelt
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.